Role of postprandial hyperglycemia in cardiovascular disease

References

• Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care21(7), 1138–1145 (1998).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339(4), 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Teff KL, Elliott SS, Matthias Tschöp M et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J. Clin. Endocrinol. Metabol.89, 2963–2972 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhong C, Yu Y, Li K. Acute effects of hyperglycaemia with and without exercise on endothelial function in healthy young men. Eur. J. Appl. Physiol.99(6), 585–591 (2007).
   PubMed Web of Science ®Google Scholar
• MacDonald PE, Joseph JW, Rorsman P. Glucose-sensing mechanisms in pancreatic β-cells. Philos. Trans. R. Soc. Lond. B. Biol. Sci.360(1464), 2211–2225 (2005).
   PubMedGoogle Scholar
• Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul. Pept.128(2), 125–134 (2005).
   PubMed Web of Science ®Google Scholar
• Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with Type 2 diabetes. Diabetes Metab.31(3 Pt 1), 233–242 (2005).
   PubMed Web of Science ®Google Scholar
• Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett.358, 219–224 (1995).
   PubMed Web of Science ®Google Scholar
• Bullock BP, Heller RS, and Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology137, 2968–2971 (1996).
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation109, 962–965 (2004).
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail.12(9), 694–699 (2006).
   PubMed Web of Science ®Google Scholar
• Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart. Regul. Pept.7, 146(1–3), 243–249 (2008).
   Google Scholar
• Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc. Drugs Ther.21(4), 253–256 (2007).
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes54(1), 146–151 (2005).
   PubMed Web of Science ®Google Scholar
• Nyström T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab.287(6), E1209–E1215 (2004).
   PubMed Web of Science ®Google Scholar
• Yu M, Moreno C, Hoagland KM et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens.21, 1125–1135 (2003).
   PubMed Web of Science ®Google Scholar
• Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab.293(5), E1289–E1295 (2007).
   PubMed Web of Science ®Google Scholar
• Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology133, 2861–2870 (1993).
   PubMed Web of Science ®Google Scholar
• Nitz I, Fisher E, Weikert C, Burwinkel B et al. Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. Mol. Nutr. Food Res.51(8), 1046–1052 (2007).
   PubMedGoogle Scholar
• Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos. Trans. R. Soc. Lond. B. Biol. Sci.361(1471), 1219–1235 (2006).
   PubMed Web of Science ®Google Scholar
• Gedulin BR, Jodka CM, Herrmann K, Young AA. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul. Pept.137(3), 121–127 (2006).
   PubMedGoogle Scholar
• Young A. Inhibition of glucagon secretion. Adv. Pharmacol.52, 151–171 (2005).
   PubMedGoogle Scholar
• Gredal C, Rosenfalck AM, Dejgaard A, Hilsted J. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed Type 2 diabetes. Scand. J. Clin. Lab. Invest.67(3), 327–336 (2007).
   PubMed Web of Science ®Google Scholar
• Polonsky KS, Sturis J, Van Cauter E. Temporal profiles and clinical significance of pulsatile insulin secretion. Horm. Res.49(3–4), 178–184 (1998).
   PubMedGoogle Scholar
• Alssema M, Schindhelm RK, Rijkelijkhuizen JM et al. Meal composition affects insulin secretion in women with Type 2 diabetes: a comparison with healthy controls. The Hoorn prandial study. Eur. J. Clin. Nutr. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Bock G, Dalla Man C, Campioni M et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes.55(12), 3536–3549 (2006).
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetic patients. J. Clin Endocrinol. Metab.86, 3717–3723 (2001).
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in Type 2 diabetic patients. Diabetes50(3), 609–613 (2001).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of Type 2 diabetes. Diabetes53(Suppl. 3), S190–S196 (2004).
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia47(3), 357–366 (2004).
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia45(8), 1111–1119 (2002).
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Knop FK, Krarup T et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J. Clin. Endocrinol. Metab.88(10), 4897–4903 (2003).
   PubMed Web of Science ®Google Scholar
• Laakso M, Zilinskaite J, Hansen T et al.; for the EUGENE2 Consortium. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia51(3), 502–511. (2008).
   PubMed Web of Science ®Google Scholar
• Rolla A. The pathophysiological basis for intensive insulin replacement. Int. J. Obes. Relat. Metab. Disord.28(Suppl. 2), S3–S7 (2004).
   Google Scholar
• Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop Type 2 diabetes. Diabetes52(10), 2461–2474 (2003).
   PubMed Web of Science ®Google Scholar
• Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and Type 2 diabetes mellitus. Metabolism.54(9), 1168–1173 (2005).
   PubMedGoogle Scholar
• Del Prato S, Marchetti P. β- and α-cell dysfunction in Type 2 diabetes. Horm. Metab. Res.36(11–12), 775–781 (2004).
   PubMedGoogle Scholar
• Hamaguchi T, Fukushima H, Uehara M et al. Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic α cells. Diabetologia34(11), 801–806 (1991).
   PubMedGoogle Scholar
• Meier JJ, Kjems LL, Veldhuis JD, Lefèbvre P, Butler PC. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes55(4), 1051–1056 (2006).
   PubMedGoogle Scholar
• Basu A, Alzaid A, Dinneen S, Caumo A, Cobeli C, Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J. Clin. Invest.97, 2351–2361 (1996).
   PubMedGoogle Scholar
• Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.287(6), E1049–1056 (2004).
   PubMedGoogle Scholar
• Mitrakou A, Kelley D, Veneman T et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes39, 1381–1390 (1990).
   PubMed Web of Science ®Google Scholar
• Meyer C, Dostou J, Welle S, and Gerich J. Role of human liver, kidney and skeletal muscle in postprandial glucose homeostasis. Am. J. Physiol. Endocrinol. Metab.282, E419–E427 (2002).
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Szoke E, Meyer C et al. Mechanisms for abnormal postprandial glucose metabolism in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.290(1), E67–E77 (2006).
   PubMed Web of Science ®Google Scholar
• Maia FF, Araújo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in Type 1 diabetic patients. Diabetes Res. Clin. Pract.75(1), 30–34 (2007).
   PubMedGoogle Scholar
• Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet. Med.20(12), 1012–1015 (2003).
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care26(3), 881–885 (2003).
   PubMed Web of Science ®Google Scholar
• Diabetes Control And Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med.329, 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J.321(7258), 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen G, Riahi Y, Alpert E, Gruzman A, Sasson S. The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes. Arch. Physiol. Biochem.113(4), 259–267 (2007).
   PubMedGoogle Scholar
• Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with Type 2 diabetes. Horm. Metab. Res.39(9), 683–686 (2007).
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in Type 2 diabetic patients: a randomized crossover study. J. Clin. Endocrinol. Metab.91(3), 837–842 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhong C, Yu Y, Li K. Acute effects of hyperglycaemia with and without exercise on endothelial function in healthy young men. Eur. J. Appl. Physiol.99(6), 585–591 (2007).
   PubMed Web of Science ®Google Scholar
• Lee IK, Kim HS, Bae JH. Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia. Int. J. Clin. Pract. (Suppl.) 129, 59–64 (2002).
   Google Scholar
• van Oostrom AJ, Sijmonsma TP, Verseyden C et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J. Lipid. Res.44(3), 576–583 (2003).
   PubMed Web of Science ®Google Scholar
• Rudofsky G Jr, Reismann P, Schiekofer S et al. Reduction of postprandial hyperglycemia in patients with Type 2 diabetes reduces NF-κaB activation in PBMCs. Horm. Metab. Res.36(9), 630–638 (2004).
   PubMed Web of Science ®Google Scholar
• Wautier JL, Boulanger E, Wautier MP. Postprandial hyperglycemia alters inflammatory and hemostatic parameters. Diabetes Metab.32(Spec. No. 2), S234–S236 (2006).
   Google Scholar
• Ceriello A, Taboga C, Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation106(10), 1211–1218 (2002).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Quagliaro L, Piconi L et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes53(3), 701–710 (2004).
   PubMed Web of Science ®Google Scholar
• Yano M, Hasegawa G, Ishii M et al. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep.9(2), 111–116 (2004).
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. J. Am. Med. Assoc.295(14), 1681–1687 (2006).
   PubMed Web of Science ®Google Scholar
• de Castro SH, Castro-Faria-Neto HC, Gomes MB. Association of postprandial hyperglycemia with in vitro LDL oxidation in non-smoking patients with Type 1 diabetes – a cross-sectional study. Rev. Diabet. Stud. 2005, 2(3), 157–164 (2005).
   PubMedGoogle Scholar
• Sakamoto T, Ogawa H, Kawano H et al. Rapid change of platelet aggregability in acute hyperglycemia: detection by a novel laser-light scattering method. Thromb. Haemost.83, 475–479, (2000).
   PubMedGoogle Scholar
• Ceriello A, Quagliaro L, Catone B et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care25, 1439–1443 (2002).
   PubMed Web of Science ®Google Scholar
• Ceriello A. Nitrotyrosine: new findings as a marker of postprandial oxidative stress. Int. J. Clin. Pract. Suppl.129, 51–58 (2002).
   Google Scholar
• Mihm MJ, Jing L, Bauer JA. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J. Cardiovasc. Pharmacol36, 182–187 (2000).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Quagliaro L, D’Amico M et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes51, 1076–1082 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson RA, Evans LM, Ellis GR et al. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet. Med.23(3), 258–264 (2006).
   PubMed Web of Science ®Google Scholar
• Schindhelm RK, Alssema M, Scheffer PG et al. Fasting and postprandial glycoxidative and lipoxidative stress are increased in women with Type 2 diabetes. Diabetes Care.30(7), 1789–1794 (2007).
   PubMed Web of Science ®Google Scholar
• Ting HJ, Stice JP, Schaff UY et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-α. Circ. Res.100(3), 381–390 (2007).
   PubMedGoogle Scholar
• Hyson DA, Paglieroni TG, Wun T, Rutledge JC. Postprandial lipemia is associated with platelet and monocyte activation and increased monocyte cytokine expression in normolipemic men. Clin. Appl. Thromb. Hemost.8(2), 147–155 (2002).
   PubMed Web of Science ®Google Scholar
• Lundman P, Boquist S, Samnegård A et al. A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr. Metab. Cardiovasc. Dis.17(3), 195–202 (2007).
   PubMed Web of Science ®Google Scholar
• Elmas E, Kälsch T, Suvajac N et al. Activation of coagulation during alimentary lipemia under real-life conditions. Int. J. Cardiol.114(2), 172–175 (2007).
   PubMedGoogle Scholar
• Eberly LE, Stamler J, Neaton JD; Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch. Intern. Med.163(9), 1077–1083 (2003).
   PubMedGoogle Scholar
• Mittermayer F, Schaller G, Pleiner J et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J. Clin. Endocrinol. Metab.92(7), 2574–2580 (2007).
   PubMedGoogle Scholar
• Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes49(7), 1231–1238 (2000).
   PubMed Web of Science ®Google Scholar
• de Jongh RT, Serné EH, Ijzerman RG, de Vries G, Stehouwer CD. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes53, 2873–2882 (2004).
   PubMed Web of Science ®Google Scholar
• Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med.326(1), 22–29 (1992).
   PubMed Web of Science ®Google Scholar
• Eschwege E, Richard JL, Thibult N et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm. Metab. Res. (Suppl. 15), 41–46 (1985).
   PubMedGoogle Scholar
• Ardigo D, Franzini L, Valtuena S, Monti LD, Reaven GM, Zavaroni I. Relation of plasma insulin levels to forearm flow-mediated dilatation in healthy volunteers. Am. J. Cardiol.97(8), 1250–1254 (2006).
   PubMedGoogle Scholar
• Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J. Clin. Invest.94, 1172–1179 (1994).
   PubMed Web of Science ®Google Scholar
• Utriainen T, Malmström R, Mäkimattila S, Yki-Järvinen H. Methodological aspects, dose–response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia38, 555–564 (1995).
   PubMed Web of Science ®Google Scholar
• Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am. J. Physiol.265, E61–E67 (1993).
   PubMed Web of Science ®Google Scholar
• Vincent MA, Dawson D et al. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes51, 42–48 (2002)
   PubMed Web of Science ®Google Scholar
• Coggins M, Lindner J, Rattigan S et al. Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by capillary recruitment. Diabetes50, 2682–2690 (2001).
   PubMed Web of Science ®Google Scholar
• Eringa EC, Stehouwer CD, van Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am. J. Physiol. Heart. Circ. Physiol.287(5), H2043–H2048 (2004).
   PubMed Web of Science ®Google Scholar
• Eringa EC, Stehouwer CD, Merlijn T, Westerhof N, Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc. Res.56(3), 464–471 (2002).
   PubMed Web of Science ®Google Scholar
• Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes41, 1076–1083 (1992).
   PubMed Web of Science ®Google Scholar
• Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J. Clin. Invest.85, 1844–1852 (1990).
   PubMed Web of Science ®Google Scholar
• Du XL, Edelstein D, Dimmeler S et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest.108, 1341–1348 (2001).
   PubMed Web of Science ®Google Scholar
• Spitaler MM, Graier WF. Vascular targets of redox signaling in diabetes mellitus. Diabetologia45, 476–494 (2002).
   PubMed Web of Science ®Google Scholar
• Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol.271, C1424–C1437 (1996).
   PubMed Web of Science ®Google Scholar
• Farkas K, Jermendy G, Herold M, Ruzicska E, Sasvári M, Somogyi A. Impairment of the NO/cGMP pathway in the fasting and postprandial state in Type 1 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes.112(5), 258–263 (2004).
   PubMedGoogle Scholar
• Hu RM, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes42, 351–358 (1993).
   PubMed Web of Science ®Google Scholar
• Ferri C, Pittoni V, Piccoli A et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J. Clin. Endocrinol. Metab.80, 829–835 (1995).
   PubMed Web of Science ®Google Scholar
• Anfossi G, Cavalot F, Massucco P et al. Insulin influences immunoreactive endothelin release by human vascular smooth muscle cells. Metabolism42, 1081–1083 (1993).
   PubMed Web of Science ®Google Scholar
• Frank HJ, Levin ER, Hu RM, Pedram A. Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells. Endocrinology133, 1092–1097 (1993).
   PubMed Web of Science ®Google Scholar
• Hopfner RL, Hasnadka RV, Wilson TW, McNeill JR, Gopalakrishnan V. Insulin increases endothelin-1-evoked intracellular free calcium responses by increased ET(A) receptor expression in rat aortic smooth muscle cells. Diabetes47, 937–944 (1998).
   PubMed Web of Science ®Google Scholar
• Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation102, 2434–2440 (2000).
   PubMed Web of Science ®Google Scholar
• Marsen TA, Egink G, Suckau G, Baldamus CA. Tyrosine-kinase-dependent regulation of the nitric oxide synthase gene by endothelin-1 in human endothelial cells. Pflügers Arch.438, 538–544 (1999).
   PubMedGoogle Scholar
• Cardoso CG Jr, Sakai D, Pinto LG et al. Neurovascular and hemodynamic responses to hyperinsulinemia in healthy postmenopausal women. Maturitas58(1), 50–58 (2007).
   PubMedGoogle Scholar
• Zimlichman R, Zaidel L, Nofech-Mozes S et al. Hyperinsulinemia induces myocardial infarctions and arteriolar medial hypertrophy in spontaneously hypertensive rats. Am. J. Hypertens.10(6), 646–653 (1997).
   PubMedGoogle Scholar
• Zimlichman R, Zeidel L, Gefel D et al. Insulin induces medial hypertrophy of myocardial arterioles in rats. Am. J. Hypertens.8(9), 915–920 (1995).
   PubMedGoogle Scholar
• Ohya Y, Abe I, Fujii K et al. Hyperinsulinemia and left ventricular geometry in a work-site population in Japan. Hypertension.27(3 Pt 2), 729–734 (1996).
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Mogi M, Iwai M. Signaling crosstalk angiotensin II receptor subtypes and insulin. Endocr. J.53(1), 1–5 (2006).
   PubMedGoogle Scholar
• Wilmink HW, Banga JD, Hijmering M, Erkelens WD, Stroes ES, Rabelink TJ. Effect of angiotensin-converting enzyme inhibition and angiotensin II Type 1 receptor antagonism on postprandial endothelial function. J. Am. Coll. Cardiol.34(1), 140–145 (1999).
   PubMedGoogle Scholar
• Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care24(3), 447– 453 (2001).
   PubMed Web of Science ®Google Scholar
• Temelkova-Kurktschiev TS, Koehler C, Schaper F, Leonhardt W, Henkel H, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose and HbA1c level. Diabetes Care23, 1830–1834 (2000).
   PubMed Web of Science ®Google Scholar
• Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care.22(6), 920–924 (1999).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis144, 229–235 (1999).
   PubMed Web of Science ®Google Scholar
• Alssema M, Schindhelm RK, Dekker JM et al. Postprandial glucose and not triglyceride concentrations are associated with carotid intima media thickness in women with normal glucose metabolism: the Hoorn prandial study. Atherosclerosis.196(2), 712–719 (2008).
   PubMed Web of Science ®Google Scholar
• Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care21, 360–367 (1998).
   PubMed Web of Science ®Google Scholar
• Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes36, 689–692 (1987).
   PubMed Web of Science ®Google Scholar
• Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care.20, 163–169 (1997).
   PubMed Web of Science ®Google Scholar
• Orencia AJ, Daviglus ML, Dyer AR, Walsh M, Greenland P, Stamler J. One-hour postload plasma glucose and risks of fatal coronary heart disease and stroke among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry (CHA) Study. J. Clin. Epidemiol.50(12), 1369–1376 (1997).
   PubMed Web of Science ®Google Scholar
• The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet354, 617–621 (1999).
   PubMed Web of Science ®Google Scholar
• de Vegt F, Dekker JM, Ruhè HG, Stehouwer CDA, Nijpels GBLM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia42, 926–931 (1999).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia39, 1577–1583 (1996).
   PubMed Web of Science ®Google Scholar
• Petrelli A, Traversa M, Bonomo K et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in Type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J. Clin. Endocrinol. Metab.91(3), 813–819 (2006).
   PubMedGoogle Scholar
• Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care22, 233–240 (1999).
   PubMed Web of Science ®Google Scholar
• Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? a Meta-analysis of Prospective Studies. Arch. Intern. Med.164(19), 2147–2155 (2004).
   PubMed Web of Science ®Google Scholar
• Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation101(17), 2047–2052 (2000).
   PubMedGoogle Scholar
• Esposito K, Nappo F, Giugliano F, Giugliano G, Marfella R, Giugliano D. Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. Am. J. Clin. Nutr.77(1), 139–143 (2003).
   PubMedGoogle Scholar
• Esposito K, Nappo F, Giugliano F et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with Type 2 diabetes mellitus. Am. J. Clin. Nutr.78(6), 1135–1140 (2003).
   PubMed Web of Science ®Google Scholar
• Padilla J, Harris RA, Fly AD, Rink LD, Wallace JP. The effect of acute exercise on endothelial function following a high-fat meal. Eur. J. Appl. Physiol.98(3), 256–262 (2006).
   PubMedGoogle Scholar
• Clegg M, McClean C, Davison GW et al. Exercise and postprandial lipaemia: effects on peripheral vascular function, oxidative stress and gastrointestinal transit. Lipids Health Dis.6(1), 30 (2007).
   PubMed Web of Science ®Google Scholar
• Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with Type 2 diabetes during treatment with either repaglinide or metformin. Diabetes. Res. Clin. Pract.60(3), 161–169 (2003).
   PubMed Web of Science ®Google Scholar
• Lund SS, Tarnow L, Stehouwer CD et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with Type 2 diabetes: results from a randomized crossover trial. Diabetes Obes. Metab.9(3), 394–407 (2007).
   PubMed Web of Science ®Google Scholar
• Caballero AE, Delgado A, Aguilar-Salinas CA et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab.89(8), 3943–3982 (2004).
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with Type 2 diabetes. Diabetes. Res. Clin. Pract.64(3), 225–228. (2004).
   PubMed Web of Science ®Google Scholar
• Katakami N, Yamasaki Y, Hayaishi-Okano R et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with Type 2 diabetes. Diabetologia47(11), 1906–1913 (2004).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Hollingdal M, Sturis J, Gall MA et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet. Med.22(10), 1408–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Li J, Tian H, Li Q et al. Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in Type 2 diabetic patients – a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes. Metab.9(4), 558–565 (2007).
   PubMed Web of Science ®Google Scholar
• Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care25(8), 1271–1276 (2002).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Van Acker KL, De Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naive Type 2 diabetes. Diabetes. Res. Clin. Pract.53(3), 141–148 (2001).
   PubMed Web of Science ®Google Scholar
• Schmitz O, Lund S, Andersen PH, Jønler M, Pørksen N. Optimizing insulin secretagogue therapy in patients with Type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care25(2), 342–346 (2002).
   PubMed Web of Science ®Google Scholar
• Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc. Diabetol.5, 9 (2006).
   PubMedGoogle Scholar
• Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide administration improves brachial reactivity in Type 2 diabetic patients. Diabetes Care28(2), 366–371 (2005).
   PubMed Web of Science ®Google Scholar
• Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab.31(3 Pt 1), 255–260 (2005).
   PubMed Web of Science ®Google Scholar
• Rizzo MR, Barbieri M, Grella R, Passariello N, Barone M, Paolisso G. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with Type 2 diabetes. A short term study. Diabetes Metab.30(1), 81–89 (2004).
   PubMedGoogle Scholar
• Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive Type 2 diabetes. Diabetes Care24, 11–15 (2001).
   PubMed Web of Science ®Google Scholar
• Landgraf R, Frank M, Bauer C, Dieken ML. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes. Int. J. Obesity.24, 38–44 (2000).
   Google Scholar
• Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation110(2), 214–219 (2004).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Anderson DM, Shelley S, Morgan R, Owens DR. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with Type 2 diabetes. Diabetes Obes. Metab.6(2), 104–113 (2004).
   PubMed Web of Science ®Google Scholar
• Mita T, Watada H, Shimizu T et al. Nateglinide reduces carotid intima-media thickening in Type 2 diabetic patients under good glycemic control. Arterioscler. Thromb. Vasc. Biol.27(11), 2456–2462 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hassman DR, Madder RD et al.; Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care27(6), 1265–1270 (2004).
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J. Clin. Endocrinol. Metab.91(3), 837–842 (2006).
   PubMed Web of Science ®Google Scholar
• Wascher TC, Schmoelzer I, Wiegratz A et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur. J. Clin. Invest.35(9), 551–557 (2005).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Taboga C, Tonutti L et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia39, 469–473 (1996).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke35, 1073–1078 (2004)
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J. Am. Med. Assoc.290(4), 486–294 (2003).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in Type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart. J.25, 10–16 (2004).
   PubMed Web of Science ®Google Scholar
• Swislocki A, Lardinois CK, Starich GH. Acarbose attenuates Basal and postprandial insulin concentrations but fails to lower blood pressure in the spontaneously hypertensive rat. Metab. Syndr. Relat. Disord.5(4), 297–304 (2007).
   PubMedGoogle Scholar
• Nakamura K, Yamagishi S, Matsui T, Inoue H. Acarbose, an α-glucosidase inhibitor, improves insulin resistance in fructose-fed rats. Drugs. Exp. Clin. Res.31(4), 155–159 (2005).
   PubMedGoogle Scholar
• Rachmani R, Bar-Dayan Y, Ronen Z, Levi Z, Slavachevsky I, Ravid M. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. Diabetes Obes. Metab.6(1), 63–68 (2004).
   PubMedGoogle Scholar
• Chiasson JL. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabet. Med.13(3 Suppl. 2), S23–S24 (1996).
   PubMedGoogle Scholar
• Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese Type 2 diabetic patients. Diabetes Metab.28(3), 195–200 (2002).
   PubMed Web of Science ®Google Scholar
• Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in Type 2 diabetes. Diabetes Obes. Metab.6(5), 384–390 (2004).
   PubMed Web of Science ®Google Scholar
• Perriello G, Pampanelli S, Porcellati F et al. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet. Med.22(5), 606–611 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenfalck AM, Thorsby P, Kjems L et al. Improved postprandial glycaemic control with insulin Aspart in Type 2 diabetic patients treated with insulin. Acta. Diabetol.37(1), 41–46 (2000).
   PubMed Web of Science ®Google Scholar
• Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in Type 1 diabetes. Diabetes Care22(5), 801–805 (1999).
   PubMed Web of Science ®Google Scholar
• Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in Type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care21(11), 1904–1909 (1998).
   PubMed Web of Science ®Google Scholar
• Griffen SC, Oostema K, Stanhope KL et al. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with Type 1 diabetes. J. Clin. Endocrinol. Metab.91(2), 485–491 (2006).
   PubMed Web of Science ®Google Scholar
• Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of Type 1 diabetes in adolescents. Clin. Ther.24(4), 629–638 (2002).
   PubMed Web of Science ®Google Scholar
• Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clin. Ther.21(3), 523–534 (1999).
   PubMed Web of Science ®Google Scholar
• Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. Diabetes Res. Clin. Pract.76(2), 304–312 (2007).
   PubMed Web of Science ®Google Scholar
• Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with Type 2 diabetes. Diabetes Care27(10), 2363–2368 (2004).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Cavarape A, Martinelli L et al. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet. Med.21(2), 171–175 (2004).
   PubMed Web of Science ®Google Scholar
• Evans M, Anderson RA, Smith JC et al. Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with Type 2 diabetes mellitus. Eur. J. Clin. Invest.33(3), 231–238 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care.28(10), 2465–2471 (2005).
   PubMedGoogle Scholar
• Forst T, Forst S, Strunk K et al. Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. J. Diabetes Complications19(3), 128–132 (2005).
   PubMedGoogle Scholar
• Ceriello A, Quagliaro L, Catone B et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care25(8), 1439–1443 (2002).
   PubMed Web of Science ®Google Scholar
• Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care28(10), 2465–2471 (2005).
   PubMedGoogle Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and meta-analysis. J. Am. Med. Assoc.298(2), 194–206 (2007).
   PubMed Web of Science ®Google Scholar
• Geelhoed-Duijvestijn PH. Incretins: a new treatment option for Type 2 diabetes? Neth. J. Med.65(2), 60–64 (2007).
   PubMedGoogle Scholar
• Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care30(6), 1344–1350 (2007).
   PubMed Web of Science ®Google Scholar
• Geelhoed-Duijvestijn PH. Incretins: a new treatment option for type 2 diabetes? Neth. J. Med.5(2), 60–64 (2007).
   Google Scholar
• Gastaldelli A, Casolaro A, Pettiti M et al. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in Type II diabetes. Clin. Pharmacol. Ther.81(2), 205–212 (2007).
   PubMedGoogle Scholar
• Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes. Diabetologia43(3), 278–284 (2000).
   PubMed Web of Science ®Google Scholar
• Rydén L, Standl E, Bartnik M et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J.28(1), 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• van Wijk J, Coll B, Cabezas MC et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in Type 2 diabetic patients. Clin. Exp. Pharmacol. Physiol.33(12), 1134–1137 (2006).
   PubMedGoogle Scholar
• Mittermayer F, Schaller G, Pleiner J et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J. Clin. Endocrinol. Metab.92(7), 2574–2580 (2007).
   PubMedGoogle Scholar
• Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care30(2), 263–269 (2007).
   PubMed Web of Science ®Google Scholar
• AACE Diabetes Mellitus Clinical Practice Gudelines Task Force. American Association of Clinical Endocrinologists medical gudelines for clinical practice for the management of diabetes mellitus. Endocrin. Pract.13 (Suppl. 1), 5–68 (2007)
   PubMedGoogle Scholar
• Nathan DM, Buse JM, Davidson MB et al. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American. Diabetes Association and the European Association for the Study of Diabetes. Diabetologia49, 1711–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with Type 2 diabetes mellitus. Horm. Metab. Res.34(9), 504–508 (2002).
   PubMed Web of Science ®Google Scholar
• Weyer C, Gottlieb A, Kim DD et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with Type 1 diabetes: a dose-timing study. Diabetes Care.26(11), 3074–3079 (2003).
   PubMed Web of Science ®Google Scholar
• Levetan C, Want LL, Weyer C et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with Type 1 diabetes intensively treated with insulin pumps. Diabetes Care26(1), 1–8 (2003).
   PubMed Web of Science ®Google Scholar
• Maggs DG, Fineman M, Kornstein J et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with Type 2 diabetes: a dose-timing study. Diabetes Metab. Res. Rev.20(1), 55–60 (2004).
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med.353, 2121–2134 (2005).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet365(9468), 1389–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet368(9548), 1660–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Damci T, Yalin S, Balci H et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese Type 2 diabetic patients. Diabetes Care.27(5), 1077–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Suter PM, Marmier G, Veya-Linder C et al. Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. Atherosclerosis.180(1), 127–135 (2005).
   PubMed Web of Science ®Google Scholar
• Tan KC, Tso AW, Tam SC, Pang RW, Lam KS. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Diabet. Med.19(11), 944–948 (2002).
   PubMedGoogle Scholar
• Porksen N, Hollingdal M, Juhl C, Butler P, Veldhuis JD, Schmitz O. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes51, S245–S254 (2002).
   PubMed Web of Science ®Google Scholar
• Meier JJ, Kjems LL, Veldhuis JD, Lefèbvre P, Butler PC. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes55(4), 1051–1056 (2006).
   PubMedGoogle Scholar
• Hollingdal M, Sturis J, Gall MA et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet. Med.22(10), 1408–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Juhl CB, Pørksen N, Hollingdal M et al. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care23(5), 675–681 (2000).
   PubMedGoogle Scholar
• Meneilly GS, Veldhuis JD, Elahi D. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.90(11), 6251–6256 (2005).
   PubMedGoogle Scholar
• Cunningham BA, Richard AM, Dillon JS et al. Glucagon-like peptide 1 and fatty acids amplify pulsatile insulin secretion from perifused rat islets. Biochem. J.369(Pt 1), 173–178 (2003).
   PubMedGoogle Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. J. Am. Med. Assoc.297(8), 842–857 (2007).
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao SP, Zhou HN, Li QZ, Li JX. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J. Cardiovasc. Pharmacol.50(1), 50–55 (2007).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Assaloni R, Da Ros R et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in Type 2 diabetic patients. Circulation111(19), 2518–2524 (2005).
   PubMed Web of Science ®Google Scholar
• Wilmink HW, Banga JD, Hijmering M, Erkelens WD, Stroes ES, Rabelink TJ. Effect of angiotensin-converting enzyme inhibition and angiotensin II Type 1 receptor antagonism on postprandial endothelial function. J. Am. Coll. Cardiol.34(1), 140–145 (1999).
   PubMedGoogle Scholar